Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “VHL-Associated Renal Cell Carcinoma”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03401788
What this trial is testing

Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

Who this might be right for
VHL - Von Hippel-Lindau SyndromeVHL Gene MutationVHL Syndrome+3 more
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 50
Early research (Phase 1)Looking for participantsNCT06553339
What this trial is testing

HS-10516 in Patients With VHL Syndrome Associated Tumors

Who this might be right for
Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
Jiangsu Hansoh Pharmaceutical Co., Ltd. 60
Not applicableWithdrawnNCT06554730
What this trial is testing

MSD Belzutifan PAS

Who this might be right for
Von Hippel Lindau Disease
Merck Sharp & Dohme LLC
Testing effectiveness (Phase 2)Study completedNCT03108066
What this trial is testing

MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)

Who this might be right for
VHL Gene MutationVHLVHL Syndrome+8 more
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 4
Early research (Phase 1)Looking for participantsNCT07300241
What this trial is testing

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Who this might be right for
Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaRCC+6 more
Neomorph, Inc 30